StockNews.AI
MIRA
StockNews.AI
148 days

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

1. MIRA announces acquisition of SKNY Pharmaceuticals, enhancing its drug pipeline. 2. The deal includes a $5 million capital infusion to bolster MIRA's finances.

2m saved
Insight
Article

FAQ

Why Bullish?

The acquisition enhances MIRA's therapeutic offerings, similar to past successful expansions in pharma companies that resulted in stock appreciation.

How important is it?

The expansion into weight loss and smoking cessation markets could significantly boost MIRA's growth potential.

Why Long Term?

While initial market reaction may be positive, the long-term potential hinges on the success of SKNY-1 in clinical trials.

Related Companies

SKNYVRTXJNJPFE
Strategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death-obesity and smoking. MIAMI, FL / ACCESS Newswire / March 24, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA"), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, announced today that it has signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals, Inc. The transaction includes a $5 million capital infusion-comprised of cash or equivalent consideration-into MIRA, reinforcing its financial position and supporting the advancement of SKNY-1, a preclinical-stage oral drug candidate for weight loss and smoking cessation.

Related News